Rapid diagnostic immunoassay for strongyloidiasis

Active Grant Awarded

Award ID
R43AI186917
Recipient
Awarding agency
Obligated
$303,250

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 13% complete
Place of performance
Framingham, MA 01702, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute of Allergy and Infectious Diseases, awarded Kephera Diagnostics LLC a grant totaling $303,250 on August 24, 2026, under Grant R43AI186917 in Assistance Listing 93.855, Allergy and Infectious Diseases Research. The Phase I work targets a rapid diagnostic immunoassay for strongyloidiasis. It will identify novel biomarkers by combining in-silico analysis with high-throughput screening to map immunodominant epitopes, and the shortlisted biomarkers will undergo further screening. The award description states that stool microscopy may lack sensitivity in chronic and low-intensity infections and that existing serological tests have inadequate sensitivity and specificity.

The period of performance runs through July 31, 2028. Place of performance is Framingham, Massachusetts 01702, USA. The recipient is a for-profit limited liability company, and the award is classified as a grant.

Description

Abstract
Strongyloidiasis, caused by the parasitic nematode strongyloides stercoralis, poses a significant public health challenge in various regions, particularly in tropical and subtropical areas. While traditionally considered endemic in these regions, recent evidence has highlighted the RE-emergence of strongyloides infection in non-endemic areas, including the united states. Unlike some other soil-transmitted helminths (STH), strongyloides due to its auto-infective lifecycle, is unique in its ability to establish a chronic and potentially life-long infection in the host. Persistent infection with strongyloides can lead to various health complications, such as gastrointestinal symptoms, respiratory issues, and skin manifestations. The most severe form of the disease, hyperinfection syndrome, is associated with high mortality rates, especially in immunocompromised individuals and those under immunosuppressive treatments. The conventional method for diagnosing strongyloidiasis involves microscopic examination of stool samples, which may lack sensitivity, especially in chronic and low-intensity infections. Existing serological tests for strongyloidiasis exhibit poor performance, with inadequate sensitivity and specificity, leading to potential underdiagnosis and misclassification of cases. This inadequacy underscores the urgent need for improved diagnostic tools to enhance the accuracy of detecting strongyloides infections. The world health organization (who) acknowledges the challenges in the existing diagnostic approaches for strongyloides, emphasizing the need for improved and more reliable methods. Towards this end, in phase I, we propose identification of new and improved novel biomarkers (aim 1) by harnessing a comprehensive approach, involving in-silico and high throughput screening to map immunodominant epitopes. The shortlisted biomarkers of interest will undergo further screening that will be used in the development of both an elisa (aim 2) and point- of-care lateral flow (LF) rapid test (aim 3). Through the subsequent development and evaluation (aim 4) of the elisa and LF assays, we seek to achieve superior sensitivity and specificity targets, using well characterized serum samples obtained from strongyloidiasis patients confirmed using both stool examination and serology. The successful implementation of these serological tests will have a direct impact by contributing to the reduction of morbidity associated with chronic infections and enhancing the overall effectiveness of public health interventions.

Quick answers

Who received award R43AI186917?

R43AI186917 was awarded to Kephera Diagnostics LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 24, 2026.

How much is award R43AI186917 worth?

$303,250 has been obligated on R43AI186917.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award